Showing 3641-3650 of 5910 results for "".
- MacuLogix Launches AMD Academyhttps://modernod.com/news/maculogix-launches-amd-academy/2479861/MacuLogix has launched its AMD Academy, an online learning community for current AdaptDx users, delivering video-based product training and a user forum to facilitate discussion of best practices and answers to user questions. “MacuLogix provides extensive, in-person training to eac
- Report: Takeda May Sell Shire Assets to Reduce Debt Following $62 Billion Purchasehttps://modernod.com/news/report-takeda-may-sell-shire-assets-to-reduce-debt-following-62-billion-purchase/2479892/According to people close to the situation, Takeda is considering selling Shire’s eye care business, including the dry eye disease treatment Xiidra (lifitegrast), once it completes the purchase of the company, Bloomberg
- Gaming for an Independent Life: Hope for Visually Impaired Children with New Computer Gamehttps://modernod.com/news/gaming-for-an-independent-life-hope-for-visually-impaired-children-with-new-computer-game/2479909/A new computer game, which developers say could help visually-impaired children lead independent lives, has been rolled out online and it is being made freely available for families, schools, and healthcare providers. The browser-based game, called Ey
- Allegro Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEOhttps://modernod.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/Allegro Ophthalmics announced that its board of directors has named Hampar Karageozian to the position of Executive Chairman and has appointed Vicken Karageozian, MD, to the position of President and Chief Executive O
- Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usabilityhttps://modernod.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/Eyenovia announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of IOP and patient usability. The EYN PG21 clinical study investigated the medication administration effectiveness and IOP lowering effect of
- Gene Mutation Found in Aqueous Humor May Detect Vitreoretinal Lymphomahttps://modernod.com/news/gene-mutation-found-in-aqueous-humor-may-detect-vitreoretinal-lymphoma/2479958/Ultrasensitive droplet digital polymerase chain reaction (ddPCR) is a potential new biopsy tool to diagnose and monitor vitreoretinal lymphoma (VRL), new research from the Netherlands suggests, according to a
- Visual Function Problems May Be More Common in Children With Dyslexiahttps://modernod.com/news/visual-function-problems-may-be-more-common-in-children-with-dyslexia/2479977/Children with developmental dyslexia (DD) may be more likely to have visual deficits than their typically developing peers, a study suggests, according to a report in Reuters. Nearly 80% of the DD group had a deficit in at least one
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a